These findings suggest that PPI use may increase the risk for IBD as well as may be associated with a decrease in the effectiveness of certain IBD treatments
Neither medication significantly affects the other's absorption, distribution, metabolism, or excretion
When combined with proper diet and exercise, TRT and GLP-1 medications can play a crucial role in promoting weight loss, improving metabolic health, and enhancing overall well-being
Furthermore, GLP-1 receptor agonists like semaglutide act on appetite centres in the brain, promoting satiety and often leading to reduced caloric intakea beneficial effect for many patients with type 2 diabetes who may also be managing their weight
Patients require baseline lipid profiles, cardiovascular risk assessment, and regular monitoring including weight tracking, lipid profile reassessment at 3-6 months and annually, blood pressure monitoring, and assessment of side effects throughout treatment
Complimentary Consultations We provide free initial consultations to determine if GLP-1 Agonist is right for you
&srotate=0)
